Ivosidenib – Another feather in the hat of treatment for acute myeloid leukemia

Jayachandran Perumal Kalaiyarasi

首页> 外文期刊>Indian Journal of Medical and Paediatric Oncology >Ivosidenib – Another feather in the hat of treatment for acute myeloid leukemia

【24h】

Ivosidenib – Another feather in the hat of treatment for acute myeloid leukemia

机译：Ivosidenib - 急性髓性白血病治疗帽的另一个羽毛

获取原文

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

The treatment of acute myeloid leukemia has undergone a paradigm shift in the past few years. Multiple new targeted and nontargeted agents have been approved in the recent past. Isocitrate dehydrogenase (IDH) mutation is one such target that has been identified, and two new drugs, ivosidenib and enasidenib have been approved. The former is an IDH1 inhibitor, and the latter is an IDH2 inhibitor. The mechanism of action, key trials, adverse events, and monitoring of ivosidenib has been discussed in this article.

机译：急性髓性白血病的治疗在过去几年中经历了范式转变。最近的多个新的目标和不确定的代理商已被批准。异柠檬酸脱氢酶（IDH）突变是已经鉴定的一种这样的靶，并且已经批准了两种新药，Ivosidenib和enaSidenib。前者是IDH1抑制剂，后者是IDH2抑制剂。本文讨论了行动机制，关键试验，不良事件和伊思凡拓的监测。

著录项

来源
《Indian Journal of Medical and Paediatric Oncology》 |2020年第4期|共3页
作者
Jayachandran Perumal Kalaiyarasi;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种
中图分类
关键词

相似文献

外文文献
中文文献
专利

1. Ivosidenib: IDHi Inhibitor for the Treatment of Acute Myeloid Leukemia [J] . SHELBY L. MERCHANT, KATHRYN CULOS, HOUSTON WYATT Journal of the advanced practitioner in oncology . 2019,第5期

机译：Ivosidenib：IDHI抑制剂治疗急性髓性白血病
2. Incidence of Differentiation Syndrome with Ivosidenib (IVO) and Enasidenib (ENA) for Treatment of Patients with Relapsed or Refractory (R/R) Isocitrate Dehydrogenase (IDH)1-or IDH2-Mutated Acute Myeloid Leukemia (AML): A Systematic Analysis By the US Food and Drug Administration (FDA) [J] . Norsworthy Kelly J., Mulkey Flora, Ward Ashley F., Blood: The Journal of the American Society of Hematology . 2018,第NovaelaTreatmentAppr期

机译：用伊昔透核（IVO）和enaSidenib（ena）分化综合征的发病率用于治疗复发或难治性（R / R）异柠檬酸脱氢酶（IDH）1-或IDH2-突变的急性髓性白血病（AML）的患者：由此进行系统分析美国食品和药物管理局（FDA）
3. Mutant Isocitrate Dehydrogenase 1 Inhibitor Ivosidenib in Combination With Azacitidine for Newly Diagnosed Acute Myeloid Leukemia (vol 39, pg 57, 2021) [J] . DiNardo C. D. Journal of Clinical Oncology . 2021,第4期

机译：突变体同亚硝酸脱氢酶1抑制剂伊富辛尼与氮杂氨酸组合用于新诊断的急性髓细胞白血病（Vol 39，PG 57,2021）
4. K-Means Clustering on 3^rd order polynomial based normalization of Acute Myeloid Leukemia (AML) and Acute Lymphocyte Leukemia (ALL) [C] . Mehdi A.M., Sehgal M.S., Zayegh A., Electrical Engineering, 2009. ICEE '09 . 2009

机译：基于3 ^{rd 多项式的K均值聚类基于急性髓细胞白血病（AML）和急性淋巴细胞白血病（ALL）的归一化}
5. Loss of Egr1 plays a role in murine leukemogenesis and may play a role in the development of acute myeloid leukemia and therapy-related acute myeloid leukemia. [D] . Joslin, John M. 2006

机译：Egr1的丢失在小鼠白血病的发生中起作用，并且可能在急性髓细胞性白血病和与治疗有关的急性髓细胞性白血病的发展中起作用。
6. Ivosidenib: IDH1 Inhibitor for the Treatment of Acute Myeloid Leukemia [O] . Shelby L. Merchant, Kathryn Culos, Houston Wyatt 2019

机译：Ivosidenib：IDH1抑制剂治疗急性髓性白血病
7. Ivosidenib – Another feather in the hat of treatment for acute myeloid leukemia [O] . Jayachandran Perumal Perumal Kalaiyarasi 2020

机译：Ivosidenib - 急性髓性白血病治疗帽的另一个羽毛

Ivosidenib – Another feather in the hat of treatment for acute myeloid leukemia

摘要

著录项

相似文献

相关主题

期刊订阅